Chiozzini et al., 2020 - Google Patents
N-Terminal Fatty Acids of NEFMUT Are Required for the CD8+ T-Cell Immunogenicity of In Vivo Engineered Extracellular VesiclesChiozzini et al., 2020
View HTML- Document ID
- 12329653708268505408
- Author
- Chiozzini C
- Manfredi F
- Arenaccio C
- Ferrantelli F
- Leone P
- Federico M
- Publication year
- Publication venue
- Vaccines
External Links
Snippet
We recently described a cytotoxic CD8+ T lymphocyte (CTL) vaccine platform based on the intramuscular (im) injection of DNA eukaryotic vectors expressing antigens of interest fused at the C-terminus of HIV-1 Nefmut, ie, a functionally defective mutant that is incorporated at …
- 210000001744 T-Lymphocytes 0 title abstract description 33
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Prado Martins et al. | In cellulo protein-mRNA interaction assay to determine the action of G-quadruplex-binding molecules | |
| Finnen et al. | CRISPR/Cas9 mutagenesis of UL21 in multiple strains of herpes simplex virus reveals differential requirements for pUL21 in viral replication | |
| Anichini et al. | Neutralizing antibody response of vaccinees to SARS-CoV-2 variants | |
| Chiozzini et al. | N-Terminal Fatty Acids of NEFMUT Are Required for the CD8+ T-Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles | |
| Seephetdee et al. | Mice immunized with the vaccine candidate HexaPro spike produce neutralizing antibodies against SARS-CoV-2 | |
| Liu et al. | Development of an LNP-encapsulated mRNA-RBD vaccine against SARS-CoV-2 and its variants | |
| Yahalom-Ronen et al. | Neutralization of SARS-CoV-2 variants by rVSV-ΔG-spike-elicited human sera | |
| Laliberté-Gagné et al. | Increased immunogenicity of full-length protein antigens through sortase-mediated coupling on the PapMV vaccine platform | |
| Sun et al. | Topology, antiviral functional residues and mechanism of IFITM1 | |
| Traylen et al. | Identification of Epstein-Barr virus replication proteins in Burkitt’s lymphoma cells | |
| Kodama et al. | Development of a DNA vaccine for melanoma metastasis by inhalation based on an analysis of transgene expression characteristics of naked pDNA and a ternary complex in mouse lung tissues | |
| Trombetta et al. | Serum neutralizing activity against B. 1.1. 7, B. 1.351, and P. 1 SARS-CoV-2 variants of concern in hospitalized COVID-19 patients | |
| Krasilnikov et al. | Design and immunological properties of the novel subunit virus-like vaccine against SARS-CoV-2 | |
| Zhang et al. | Immunogenicity evaluating of the multivalent covid-19 inactivated vaccine against the sars-Cov-2 variants | |
| Shi et al. | Screening of efficient adjuvants for the RBD-based subunit vaccine of SARS-CoV-2 | |
| Helle et al. | Intercellular transmission of naked viruses through extracellular vesicles: focus on polyomaviruses | |
| Khan et al. | Trivalent SARS-CoV-2 S1 subunit protein vaccination induces broad humoral responses in BALB/c Mice | |
| Thimmiraju et al. | A recombinant protein XBB. 1.5 RBD/Alum/CpG vaccine elicits high neutralizing antibody titers against omicron subvariants of SARS-CoV-2 | |
| Chang et al. | Induction of broadly cross-reactive antibodies by displaying receptor binding domains of SARS-CoV-2 on virus-like particles | |
| Silva et al. | Standardization and Key Aspects of the Development of Whole Yeast Cell Vaccines | |
| Geerling et al. | Current flavivirus research important for vaccine development | |
| Sanina et al. | Modulation of immunogenicity and conformation of HA1 subunit of influenza A virus H1/N1 hemagglutinin in tubular immunostimulating complexes | |
| Tiwarekar et al. | KDELR2 competes with measles virus envelope proteins for cellular chaperones reducing their chaperone-mediated cell surface transport | |
| Manfredi et al. | Activation of anti-SARS-CoV-2 human CTLs by extracellular vesicles engineered with the N viral protein | |
| Chiozzini et al. | The C-Terminal Domain of Nefmut Is Dispensable for the CD8+ T Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles |